Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme
Sign Up to like & getrecommendations! Published in 2017 at "Liver International"
DOI: 10.1111/liv.13383
Abstract: Optimally effective treatment for hepatitis C virus genotype 3 (GT3) is urgently needed, particularly in advanced liver disease. Daclatasvir plus sofosbuvir was efficacious in phase 3 studies. Real‐world data for daclatasvir+sofosbuvir in advanced GT3 infection… read more here.
Keywords: daclatasvir; daclatasvir plus; plus sofosbuvir; hepatitis virus ... See more keywords